tm logo
UPONUREG
REGISTERED

on 12 Feb 2024

Last Applicant/ Owned by

CELGENE CORPORATION

Route 206 & Province Line RoadPrinceton, NJ 08543

US

Serial Number

2012266 filed on 18th Feb 2020

Registration Number

TMA1221001 registered on 12th Feb 2024

Registration expiry Date

12th Feb 2034

Correspondent Address

SUITE 16001 FIRST CANADIAN PLACE100 KING STREET WESTTORONTO

ONTARIO

CA

M5X1G5

UPONUREG

Trademark usage description

pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, heart failure, thrombosi Read More

Classification Information


Class [005]
Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, heart failure, thrombosis, stroke, cancer, respiratory diseases, auto-immune diseases, rheumatoid arthritis, lupus, inflammatory bowel disease, solid organ transplant rejection, hepatitis, fibrosis, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; pharmaceutical preparations for human use for the treatment and prevention of metabolic disorders, namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome; pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, anti-inflammatories, anti-infectives, central nervous system depressants, central nervous system stimulants, anti-psychotics, cytokine inhibitory drugs; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for the treatment of cancer, respiratory diseases, auto-immune diseases, and for the prevention and treatment of solid organ transplant rejection; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for use as anti infectives, and for use as anti-inflammatories; diagnostic pharmaceutical preparations for human use for increasing the heart rate and for use as medical imaging contrast agents; pharmaceutical preparations for human use that modulate the immune system; pharmaceutical preparations for human use, namely, immunotherapies for the treatment of cancer; pharmaceutical preparations for use in immunotherapies; pharmaceutical preparations for use in T-cell immunotherapy; pharmaceutical preparations for use in cell therapy; pharmaceutical preparations for human use namely T-cells for medical purposes; pharmaceutical preparations for human use namely diagnostic kits consisting primarily of cells for medical laboratory use; Pharmaceutical preparations for human use for treatment and prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use namely antivirals for treatment and prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; pharmaceutical preparations for human use namely monoclonal antibodies.


Classification kind code

11

Mark Details


Serial Number

2012266

Mark Type

Trademark

Legal History


Show more

Action TakenStatus
Submitted for opposition 190
on 12th Feb 2024
Registration Pending
Submitted for opposition 42
on 22nd Nov 2023
Advertised
Submitted for opposition 27
on 27th Oct 2023
Approval Notice Sent
Submitted for opposition 26
on 27th Oct 2023
Approved
Submitted for opposition 22
on 11th Apr 2023
Search Recorded
Submitted for opposition 20
on 11th Apr 2023
Examiner's First Report
Submitted for opposition 287
on 20th Oct 2022
Pre-Assessment Letter Sent
Submitted for opposition 31
on 02th Mar 2020
Formalized
Submitted for opposition 1
on 19th Feb 2020
Created
Submitted for opposition 30
on 18th Feb 2020
Filed